



# COVERAGE DETERMINATION REQUEST FORM

EOC ID:  
Step Therapy Exception - EL

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

|                           |  |               |
|---------------------------|--|---------------|
| <b>Patient Name:</b>      | <b>Prescriber Name:</b>                  |               |
| Member/Subscriber Number: | Fax:                                     | Phone:        |
| Date of Birth:            | Office Contact:                          |               |
| Group Number:             | NPI:                                     | State Lic ID: |
| Address:                  | Address:                                 |               |
| City, State ZIP:          | City, State ZIP:                         |               |
| Primary Phone:            | Specialty/facility name (if applicable): |               |

**\*Please note that Elixir will process the request as written, including drug name, with no substitution.**

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

**Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.**

Q1. Is this request for initial or continuing therapy?

Initial therapy

Continuing therapy

Q2. For CONTINUING THERAPY, please provide the start date:

Q3. Please indicate the patient's diagnosis for the requested medication:

Q4. Please indicate below which medication you are requesting a Step Therapy exception for:

Cholesterol Step Therapy

Proton Pump Inhibitors

ARB Step Therapy

Tricor

Ambien CR

Uloric

Boniva/Actonel

Rhinocort

Celebrex

Other

Daytrana

Q5. If the medication is OTHER, please specify below:

Q6. Please indicate below which step one medications have been tried and failed:

Omeprazole

NSAIDS

Pantoprazole

Alendronate



# COVERAGE DETERMINATION REQUEST FORM

EOC ID:  
Step Therapy Exception - EL

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

|  |  |
|--|--|
| <b>Patient Name:</b>   | <b>Prescriber Name:</b>  |
| <input type="checkbox"/> Prilosec OTC/Omeprazole OTC<br><input type="checkbox"/> Lovastatin<br><input type="checkbox"/> Simvastatin<br><input type="checkbox"/> Pravastatin<br><input type="checkbox"/> Zolpidem<br><input type="checkbox"/> losartan/HCT, irbesartan, valsartan/HCT | <input type="checkbox"/> Fenofibrate, Triglide or Antara<br><input type="checkbox"/> Oral ADD/ADHD medication(s)<br><input type="checkbox"/> Fluticasone, Flunisolide, Nasonex, Veramyst or Nasacort AQ<br><input type="checkbox"/> Allopurinol<br><input type="checkbox"/> Venlafaxine IR or ER<br><input type="checkbox"/> Other |
| Q7. If the medication is OTHER, please specify below:  |  |
| Q8. Please indicate the dose and the dates of the trial for the specific step one drug or formulary alternative below:   |  |
| Q9. If the patient has NOT previously tried and failed a step one medication or a formulary alternative, please indicate below why the patient needs to have an exception to the step therapy:   |  |

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document